Former FDA Commissioner Scott Gottlieb defended drug maker Pfizer’s choice to not investigate signals that its anti-inflammatory drug Enbrel appeared to reduce the risk of Alzheimer’s, as the Washington Post reported on June 4. In a discussion hosted by the Post on Tuesday (June 11), Gottlieb said the Pfizer story opens up a wider question about whether drug makers are obliged to investigate or publish any kind of potential treatment signal that researchers encounter. “I think the answer...